Chemotherapy Foundation Symposium XXVI: Innovative cancer therapy for tomorrow - Chronic myelogenous leukemia: Is there hope after therapeutic failure with imatinib (Gleevec)?

Marvin M. Goldenberg; Jorges Cortes

Chemotherapy Foundation Symposium XXVI: Innovative cancer therapy for tomorrow - Chronic myelogenous leukemia: Is there hope after therapeutic failure with imatinib (Gleevec)?

Marvin M. Goldenberg
, Jorges Cortes

Research output: Contribution to journal › Article › peer-review

Abstract

Studies of other inhibitors, such as PHA-739358, AP-24534, and DCC-2036, are expected to begin shortly. Each agent that was described in this section offers hope in cases of treatment failure with imatinib. The major challenges are to prevent the development of imatinib resistance and to find ways to eradicate all evidence of disease in all patients.

Original language	English (US)
Pages (from-to)	714-719
Number of pages	6
Journal	P and T
Volume	33
Issue number	12
State	Published - Dec 2008
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

ASJC Scopus subject areas

Pharmacology (medical)

Cite this

@article{4fe0c732d03041e8bf2def86d0d1dfbb,

title = "Chemotherapy Foundation Symposium XXVI: Innovative cancer therapy for tomorrow - Chronic myelogenous leukemia: Is there hope after therapeutic failure with imatinib (Gleevec)?",

abstract = "Studies of other inhibitors, such as PHA-739358, AP-24534, and DCC-2036, are expected to begin shortly. Each agent that was described in this section offers hope in cases of treatment failure with imatinib. The major challenges are to prevent the development of imatinib resistance and to find ways to eradicate all evidence of disease in all patients.",

author = "Goldenberg, \{Marvin M.\} and Jorges Cortes",

year = "2008",

month = dec,

language = "English (US)",

volume = "33",

pages = "714--719",

journal = "P and T",

issn = "1052-1372",

publisher = "MediMedia USA Inc.",

number = "12",

}

TY - JOUR

T1 - Chemotherapy Foundation Symposium XXVI

T2 - Innovative cancer therapy for tomorrow - Chronic myelogenous leukemia: Is there hope after therapeutic failure with imatinib (Gleevec)?

AU - Goldenberg, Marvin M.

AU - Cortes, Jorges

PY - 2008/12

Y1 - 2008/12

N2 - Studies of other inhibitors, such as PHA-739358, AP-24534, and DCC-2036, are expected to begin shortly. Each agent that was described in this section offers hope in cases of treatment failure with imatinib. The major challenges are to prevent the development of imatinib resistance and to find ways to eradicate all evidence of disease in all patients.

AB - Studies of other inhibitors, such as PHA-739358, AP-24534, and DCC-2036, are expected to begin shortly. Each agent that was described in this section offers hope in cases of treatment failure with imatinib. The major challenges are to prevent the development of imatinib resistance and to find ways to eradicate all evidence of disease in all patients.

UR - https://www.scopus.com/pages/publications/58449125189

UR - https://www.scopus.com/pages/publications/58449125189#tab=citedBy

M3 - Article

AN - SCOPUS:58449125189

SN - 1052-1372

VL - 33

SP - 714

EP - 719

JO - P and T

JF - P and T

IS - 12

ER -

Chemotherapy Foundation Symposium XXVI: Innovative cancer therapy for tomorrow - Chronic myelogenous leukemia: Is there hope after therapeutic failure with imatinib (Gleevec)?

Abstract

UN SDGs

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this